Журнал "Почки" том 10, №1

Îãëÿä / Review
26. Tanaka T., Narazaki M., Kishimoto T. Interleukin (IL-6)
Immunotherapy. Cold Spring Harb. Perspect. Biol. 2018 Aug. 10 (8).
a028456. doi: 10.1101/cshperspect.a028456.
27. Akioka S. Interleukin-6 in juvenile idiopathic arthritis.
Mod. Rheumatol. 2019 Mar. 29 (2). P. 275-286. doi:
10.1080/14397595.2019.1574697.
28. Gohda T., Makita Y., Shike T. et al. Dilazep hydrochloride,
an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial
cell IL-6 secretion and proliferation. Kidney Blood Press Res.
2001. 24 (1). P. 33-8. doi: 10.1159/000054203.
29. Su H., Lei C.T., Zhang C. Interleukin-6 Signaling Pathway
and Its Role in Kidney Disease: An Update. Front Immunol. 2017. 8.
P. 405. doi:10.3389/fimmu.2017.00405
30. Lu H., Zhou J. HBV X gene transfection upregulates IL-1beta
and IL-6 gene expression and induces rat glomerular mesangial cell
proliferation. J. Huazhong Univ. Sci Technolog. Med. Sci. 2008 Jun.
28 (3). P. 247-50. doi: 10.1007/s11596-008-0304-5.
31. Kawasaki Y., Suzuki J., Sike T. et al. Bucillamine-induced
nephropathy in a child with juvenile rheumatoid arthritis and Kartagener’s
syndrome. Pediatrics international: Official Journal of the Japan
Pediatric Society. 2000. 42 (3). P. 316-8. DOI: 10.1046/j.1442-
200x.2000.01211.x
32. Suzuki K., Tanaka H., Ito E. et al. Therapy-related membranous
nephropathy in juvenile idiopathic arthritis with Turner syndrome.
Pediatr. Int. 2004 Jun. 46 (3). P. 377-9. doi: 10.1111/j.1442-
200x.2004.01906.x.
33. Foster B.J., Duffy C.M., Sharma A.K. Systemic juvenile rheumatoid
arthritis complicated by two different renal lesions. Pediatr.
Nephrol. 1998 Feb. 12 (2). P. 113-6. doi: 10.1007/s004670050416.
34. Gedalia A., Mendez E.A., Craver R. et al. Renal involvement
in juvenile rheumatoid arthritis: report of two cases. Clin. Rheumatol.
2001. 20 (2). P. 153-6. doi: 10.1007/pl00011196.
35. Varma S. Juvenile rheumatoid arthritis with focal segmental
glomerulosclerosis: a rare association. Pediatr. Nephrol. 2010. 25.
P. 2189-2190. https://doi.org/10.1007/s00467-010-1504-3
36. Lévy M., Prieur A.-M., Gubler M.-C. et al. Renal Involvement
in Juvenile Chronic Arthritis: Clinical and Pathologic Features.
American Journal of Kidney Diseases. 1987. 9 (2). P. 138-146.
https://doi.org/10.1016/S0272-6386 (87)80091-4.
37. Kari J.A., Bamashmous H., Mahan J.D. Steroid-sensitive
nephrotic syndrome and juvenile idiopathic arthritis. Pediatr. Nephrol.
2002 Nov. 17 (11). P. 975-6. doi: 10.1007/s00467-002-0957-4.
38. Ito S., Tsutsumi A., Harada T. et al. Long-term remission
of nephrotic syndrome with etanercept for concomitant juvenile idiopathic
arthritis. Pediatr. Nephrol. 2010 Oct. 25 (10). P. 2175-7. doi:
10.1007/s00467-010-1571-5.
39. Kim S.H., Park S.J., Han K.H. et al. Pathogenesis of minimal
change nephrotic syndrome: an immunological concept. Korean J. Pediatr.
2016 May. 59 (5). P. 205-11. doi: 10.3345/kjp.2016.59.5.205.
40. Otero G.A., Esteban J., Salgado J. et al. Chronic juvenile
arthritis and minimal change glomerulonephritis (MCGN), the same
pathogenic basis? Anales de Medicina Interna. 1991. 8 (8). P. 413-
414. PMID: 1768756.
41. Shi D., Zhang Y., Liu D. et al. Analysis of the clinical characteristics
of arthritis with renal disease caused by a NPHS2 gene
mutation. Clin. Rheumatol. 2021. https://doi.org/10.1007/s10067-
020-05574-7
42. Mene P., Franeta A.-J., Conti G. et al. Extracapillary glomerulonephritis
during etanercept treatment for juvenile psoriatic arthritis.
Clinical and Experimental Rheumatology. 2010. 18 (2010). P. 91-
93. https://doi.org/10.2165/00128415-201013030-00050].
Получено/Received 04.01.2021
Рецензировано/Revised 15.01.2021
Принято в печать/Accepted 19.01.2021
Information about authors
Borysova Tamara, MD, PhD, Professor, Head of the Department of pediatrics 2, State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; e-mail:
toma.inform@gmail.com; phone: +380504225709; https://orcid.org/0000-0001-8347-4348
Samsonenko Svitlana, Assistant the Department of pediatrics 2, State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; e-mail:
ssindorella2@gmail.com, 420@dsma.dp.ua; phone: +38(0562)39-23-99, mob. phone: +38(068)4226279; https://orcid.org/0000-0001-6812-0939
Liudmyla Vakulenko, MD, PhD, Associated Professor at the Department of pediatrics 2, State Institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Vernadsky st., 9, Dnipro,
49044, Ukraine; e-mail: vakulenkol@ukr.net; 420@dsma.dp.ua; phone: +38(0562)39-23-99, mob. phone: +38(097)1588888; https://orcid.org/0000-0003-3823-6134
Makoviichuk Oleksii, Assistant at the Department of Propaedeutics of children's diseases, State Institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Vernadsky st., 9, Dnipro,
49044, Ukraine; e-mail: vakulenkol@ukr.net; ssindorella2@gmail.com; 420@dsma.dp.ua; phone: +38(0562)39-23-99, mob. phone: +38(067)6364242; https://orcid.org/0000-0002-4641-8838
T.P. Borysova, S.V. Samsonenko, L.I. Vakulenko, O.O. Makoviichuk
SI “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine
Renal glomerular lesions in children with juvenile rheumatoid arthritis
(literature review)
Abstract. The literature review describes the different forms
of glomerulonephritis (GN) in children with polyarticular and
systemic forms of juvenile rheumatoid arthritis (JRA). In the
available literature, there are 21 clinical cases of GN: ANCAassociated
GN, mesangial proliferative GN, including IgA- and
IgM-nephropathy, membranous nephropathy, focal-segmental
glomerulosclerosis, minimal change disease, and extracapillary
GN. The mechanism of glomerular lesions in JRA is explained by
hyperproduction of pro-inflammatory cytokines and by nephrotoxic
action of basal anti-inflammatory medications. The clinical
manifestations and the effectiveness of treatment of each variant of
GN in children with JRA were analyzed in detail. Most publications
are devoted to ANCA-associated GN, which developed in
patients with a torpid course and a high activity of polyarticular
and systemic forms of JRA. The peculiarity of ANCA-associated
GN was the presence of hypercreatininemia and in almost half of
cases the development of terminal renal failure, despite conducted
immunosuppressive therapy. Single cases of other variants of GN
were described more than 10 years ago. Proteinuria and the rare
nephrotic syndrome were clinically observed, which was the rea-
Òîì 10, ¹ 1, 2021
www.mif-ua.com, http://kidneys.zaslavsky.com.ua 71